Gut Liver.  2021 May;15(3):440-450. 10.5009/gnl19393.

Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution

  • 1Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea.
  • 2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • 3Department of Internal Medicine, Good Samsun Hospital, Busan, Korea.
  • 4Liver Center, Pusan National University Yangsan Hospital, Yangsan, Korea.
  • 5Department of Laboratory Medicine, College of Medicine, Pusan National University, Busan, Korea.


Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea.
This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined.
We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eightythree patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naïve, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild.
These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities.


Hepatitis C; chronic; Glecaprevir; Pibrentasvir; Sustained virologic response
Full Text Links
  • GNL
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error